NCT06788652View on ClinicalTrials.gov

A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

February 4, 2025

Primary Completion Date

September 30, 2044

Study Completion Date

September 30, 2044

Conditions
Mantle Cell Lymphoma (MCL)
Interventions
BIOLOGICAL

Lisocabtagene maraleucel

According to US Prescribing Information

Trial Locations (1)

53226

RECRUITING

Center for International Blood and Marrow Transplant Research (CIBMTR), Milwaukee

All Listed Sponsors
lead

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

INDUSTRY